Life-Changing Early Detection Now Available for Around Six Babies Born with SMA in Ireland Each Year
Ireland has begun screening newborn babies for spinal muscular atrophy (SMA) as part of the National Newborn Bloodspot Screening Programme, in a development hailed as a "remarkable day" for infant health — with early detection described as life-changing for affected families, as it allows treatment to begin before irreversible damage occurs.
What Has Changed
From April 2026, the heel prick test — a simple blood test taken from a newborn's heel within days of birth — now screens for SMA alongside Severe Combined Immunodeficiency (SCID), bringing the total number of conditions screened to eleven. Health Minister Jennifer Carroll MacNeill announced the expansion, noting that equipment for the rollout had been purchased and installed, with laboratory verification ongoing. It is estimated that around six babies are born with SMA in Ireland annually.
Why Early Detection Matters
SMA is a rare genetic condition that causes severe muscle degeneration and can be fatal by the age of two if untreated. The condition results from the body's inability to produce enough survival motor neuron (SMN) protein, leading to the degeneration of motor neurons and progressive muscle weakness. Early diagnosis is considered life-changing because it enables immediate treatment — before the irreversible damage that occurs with delayed diagnosis.
The difference early detection makes is stark. One family shared their experience where a child diagnosed at eight weeks suffered irreversible damage, while another child diagnosed before birth and treated within days lives without disabilities. Several cutting-edge treatments are now available in Irish hospitals, including Spinraza, Nusinersen, and Evrysdi, which help the body produce more SMN protein, as well as gene therapy for some babies.
A Long-Awaited Development
The recommendation to add SMA to the newborn screening programme was accepted in November 2023 by then Health Minister Stephen Donnelly, making the April 2026 implementation a long-awaited milestone for advocacy groups like SMA Ireland and families affected by the condition. Minister Carroll MacNeill has committed to further expanding the programme, with the National Screening Advisory Committee already assessing additional conditions.
What's Next
The Health Information and Quality Authority (HIQA) is currently assessing the inclusion of congenital adrenal hyperplasia (CAH) as a further addition to the screening programme. The expansion of newborn screening is part of the HSE's 2026 National Service Plan, backed by a €29 billion budget, which also includes a €3.8 billion investment in disability services — a 20% increase from 2025. Full RTÉ report.
